Hormonal Treatment

Dienogest + Estradiol Valerate (QLAIRA) 30 Tablet

$144.00

Qlaira has a well-established safety profile when used as directed. However, like all hormonal contraceptives, it may be associated with certain risks, including an increased risk of blood clots, cardiovascular events, and certain cancers. Patients should be informed of these risks before starting treatment.

Quantity

Dienogest + Estradiol Valerate (QLAIRA) 30 Tablet quantity

Add to cart

Tag:

Dienogest + Estradiol Valerate QLAIRA

Description

Qlaira is a combined oral contraceptive (COC) medication containing the active ingredients dienogest and estradiol valerate. This contraceptive is designed to prevent pregnancy by inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering the endometrium to discourage implantation. Qlaira is prescribed primarily for contraception but may also offer additional benefits such as relief from menstrual symptoms and improvement of menstrual regularity.

Key Features:

• Combined Oral Contraceptive (COC): Qlaira is a combined hormonal contraceptive containing both progestogen (dienogest) and estrogen (estradiol valerate). This combination effectively prevents pregnancy by suppressing ovulation, thickening cervical mucus to impede sperm penetration, and altering the endometrium to discourage implantation.
• Menstrual Symptom Management: In addition to contraception, Qlaira is indicated for the management of menstrual symptoms such as heavy menstrual bleeding (menorrhagia), irregular menstrual cycles, and dysmenorrhea (painful periods). The hormonal components in Qlaira help regulate the menstrual cycle and reduce the severity of these symptoms.
• Dose Variability: Qlaira is available in a 28-day regimen pack containing 26 active tablets with varying doses of estradiol valerate (ranging from 1.5 mg to 3 mg) and 2 inactive tablets. The variable dosing regimen mimics the natural hormonal fluctuations throughout the menstrual cycle, potentially reducing side effects and improving tolerability.
• Oral Administration: Qlaira is administered orally, with one tablet taken daily at the same time each day for 28 consecutive days. After completing one pack, a new pack is started immediately without a break, ensuring continuous contraceptive coverage.
• Efficacy: Clinical studies have demonstrated the high efficacy of Qlaira in preventing pregnancy when taken as directed. Additionally, Qlaira has been shown to provide effective relief from menstrual symptoms, including heavy menstrual bleeding and dysmenorrhea.
• Safety Profile: Qlaira has a well-established safety profile when used as directed. However, like all hormonal contraceptives, it may be associated with certain risks, including an increased risk of blood clots, cardiovascular events, and certain cancers. Patients should be informed of these risks before starting treatment.
• Patient Education: Patients prescribed Qlaira should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to the dosing regimen. Patients should also be counseled on the use of additional contraceptive methods, such as condoms, to reduce the risk of sexually transmitted infections.
• Consultation with Healthcare Provider: Treatment with Qlaira should be initiated and monitored by a qualified healthcare provider experienced in contraceptive management. Close monitoring and regular follow-up are essential to ensure optimal contraceptive efficacy and patient safety.
• Access and Affordability: Efforts should be made to ensure equitable access to Qlaira for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to effective contraception is crucial for reproductive health and family planning.